Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Nabriva Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
NBRVF's Cyclically Adjusted PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 5.685 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Nabriva Therapeutics's adjusted revenue per share data of for the fiscal year that ended in Dec22 was $13.299. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $20.57 for the trailing ten years ended in Dec22.
Shiller PE for Stocks: The True Measure of Stock Valuation
Nabriva Therapeutics (OTCPK:NBRVF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Nabriva Therapeutics Cyclically Adjusted PS Ratio Related Terms
Nabriva Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Nabriva Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nabriva Therapeutics Cyclically Adjusted PS Ratio Chart
NBRVF vs BXRX, INM, ADTX: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Nabriva Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's Cyclically Adjusted PS Ratio falls into.
Nabriva Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.00 mean?
Nabriva Therapeutics (NBRVF) has a Cyclically Adjusted PS Ratio of 0.00 as of Aug. 13, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' Cyclically Adjusted PS Ratio too high?
Nabriva Therapeutics' current Cyclically Adjusted PS Ratio is 0.00. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' Cyclically Adjusted PS Ratio compare to BXRX and INM?
Nabriva Therapeutics' Cyclically Adjusted PS Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Cyclically Adjusted PS Ratio is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.69, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nabriva Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nabriva Therapeutics's current Cyclically Adjusted PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current Cyclically Adjusted PS Ratio of 0.00. The current Cyclically Adjusted PS Ratio is 0.00. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current Cyclically Adjusted PS Ratio is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score
Get the complete analysis for NBRVF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NBRVF has been successfully added to your 
